

Suspected fetal macrosomia and the risk of shoulder dystocia as an indication for cesarean section

Abstract

Macrosomia is associated with increased risk for perinatal complications including prolonged labor, shoulder dystocia, perinatal mortality and maternal morbidity including cesarean delivery, severe postpartum hemorrhage, and vaginal lacerations. Among maternal risk factors for fetal macrosomia are high body-mass index, diabetes mellitus, postterm pregnancy, previous macrosomic infant. Shoulder dystocia occurs in 0.2-3% of all births and represents an obstetric emergency. Although, in general, clinical estimates of birth weight perform favorably, ultrasound immediately prior to labour is more accurate at predicting the high birth-weight fetus. Ultrasound measurement of abdominal circumference and fetal biometry are the only practical methods used to detect fetal weight over 4000 g, but they are characterized by low sensitivity, low positive predictive value and high negative predictive value. Serial sonographic measurements can increase the positive predictive value. By combining three-dimensional volumetric measurements with two-dimensional measurements, should increase the ability to predict macrosomia. Nowadays, clinicians needs to examine all the information available to take a decision on whether the risk of macrosomia and shoulder dystocia is high, and if so then an elective caesarean section is indicated. Predicting fetal macrosomia does not imply that elective caesarean section is the method of choice, but it should be made clear to the couple that elective caesarean section is the low-risk option. Important to note is that each woman should be informed of the particular risks associated with a macrosomic fetus and shoulder dystocia. The mother should be supported in the decision, because it is a situation in which maternal autonomy is paramount.

Keywords: macrosomia, shoulder dystocia, cesarean section

Introduction

Macrosomia refers to growth beyond a specific threshold⁽¹⁾. In developed countries, the most common thresholds that have been proposed are weight above 4000 g or 4500 g^(2,3). A grading system has also been suggested: grade 1 for infants 4000 to 4499 g, grade 2 for 4500 to 4999 g, and grade 3 for over 5000 g⁽⁴⁾. The American College of Obstetricians and Gynecologists supports use of the 4500 g threshold for diagnosis of macrosomia because morbidity increases sharply beyond this weight, but acknowledges there is some increased risk of morbidity at weights >4000 g⁽⁵⁾. Such a birth weight is associated with an increased risk for maternal morbidity and a number of perinatal complications including prolonged labor, shoulder dystocia with brachial palsy, facial nerve palsy, fractures of the clavicular and humeral bones, perinatal mortality, asphyxia^(6,7) and cesarean section. Delivery of large fetuses is still a source of anxiety among obstetricians, despite major progress in obstetrics in the last century. The worldwide prevalence of birth of infants ≥ 4000 g is about 9 percent and about 0.1 percent of newborns weigh ≥ 5000 g, with wide variations among countries⁽⁸⁾. The prevalence of birth weight ≥ 4000 g in developing countries is typically 1 to 5 percent, but ranges from 0.5 to 14.9 percent⁽⁹⁾. In population statistics, normal weight is defined as between the 10th and 90th percentile for gestational age (i.e. assuming a normal

population distribution). Using a statistical approach, any fetus weighing >90th percentile for gestational age would be considered large for gestational age (LGA). The use of country-specific centiles may be the best approach, particularly in the developing world, since it accounts for differences between populations⁽¹⁰⁾. The 95th and 97.75th percentiles have also been used as thresholds. Weight percentile for gestational age is the best means for identifying the preterm or term macrosomic fetus.

About 70 percent of infants with birth weight over 4500 grams are male⁽¹¹⁾. Racial and ethnic differences influence birth weight. The proportion of newborns with birth weight >4000 g has increased during the past two decades, in parallel with an increasing prevalence of maternal body mass index (BMI) ≥ 25 kg/m² related to alimentary habits and with an increase in maternal age⁽¹²⁾. Although the fetal genome is the central controller of growth in an uncomplicated pregnancy⁽¹³⁾, maternal clinical characteristics and fetal gender are associated with fetal growth^(14,15). Both transient and permanent fetal and maternal injuries are seen as a consequence of delivering a large fetus, and for the neonate it might result in impairment to health later in life⁽¹⁶⁾.

Macrosomia occurs in approximately 42-62% of pregnancies complicated by Type-1 diabetes mellitus (DM1)⁽¹⁷⁻¹⁹⁾, in 30-56% of pregnancies complicated by Type-2

Simona Vladareanu¹, Cristian Andrei², Dan Navolan³, Diana Badiu⁴, Tony Hangan⁴, Radu Vladareanu²

1. Department of Neonatology, Elias University Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest (Romania); e-mail: simconst69@gmail.com

2. Department of Obstetrics and Gynecology, Elias University Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest (Romania); e-mail: viadareanu@gmail.com

3. Department of Obstetrics and Gynecology and Neonatology, and "Victor Babes" University of Medicine and Pharmacy Timisoara, City Emergency Clinical Hospital Timisoara, Timisoara (Romania); e-mail: navolan@yahoo.com

4. Faculty of Medicine, "Ovidius" University of Constanta (Romania); e-mail: dianabadiu@yahoo.com; tony@medcon.ro; tonyhangan@yahoo.com

*All authors have equally contributed to this work.

Received: January 15, 2015
Revised: February 02, 2015
Accepted: March 04, 2015

diabetes mellitus (DM2)⁽²⁰⁾ and in 10-20% of pregnancies complicated by gestational diabetes mellitus (GDM)⁽²¹⁾. In women with DM1 and DM2, indicators of poor placentation in early pregnancy are related to normal birth weight, and indicators of normal placentation to increased birth weight (i.e. fetal overgrowth in both instances)⁽²²⁾. The growth pattern of fetuses of women with diabetes, especially when glycemic control has been poor, is different from that in fetuses of nondiabetic mothers⁽²³⁾. There is an altered fetal growth in macrosomic and non-macrosomic fetuses of women with DM1, DM2 and GDM. Growth profiles differ among these groups, with the most prominent growth deviations in fetuses of women with DM1, probably due to poor glucose control. Maternal hyperglycemia due to diabetes leads to increased secretion of insulin by the fetus and muscle growth, deposition of excess fat and organomegaly in the fetus. Previous studies on fetal macrosomia have confirmed that preconception and first-trimester glucose control has the greatest effect on fetal size⁽²⁴⁾. Macrosomic infants of diabetic mothers have increased mass, larger shoulders and greater amounts of body fat, decreased head-to-shoulder ratio, more muscle growth in the inter-scapular areas and abdomen after 32 weeks and increased skin folds in the upper extremities⁽²⁵⁾. Increased fetal size starts from the second trimester onwards, and that the difference in size persists despite improvements in diabetic control⁽²⁶⁾. Several studies have used this information in an attempt to predict the risk of shoulder dystocia in diabetic pregnancies, but no method has proven to be reliable until present⁽²⁷⁾. Accelerated mid trimester growth in abdominal circumference (AC) was often associated with the birth of a heavy or LGA baby, and poor maternal glycemic control (HbA1c >7.0%) in early pregnancy was a modest predictor of both. These morphologic differences are responsible for substantially higher rates of shoulder dystocia among macrosomic fetuses of diabetic pregnancies compared to macrosomic fetuses of non-diabetic pregnancies⁽²⁸⁾.

Higher maternal age and obesity are other risk factors for excessive fetal growth. In 2004, a large review of maternal and neonatal data in the USA⁽²⁹⁾ showed that the statistical association between GDM and LGA infants strengthened as pre-gravid BMI increased, thus suggesting that maternal overweight was an independent risk factor for LGA newborns among those patients. An increase in BMI 25% during pregnancy has a sensitivity of 86.2%, specificity of 93.6%, positive predictive value of 71.4% and negative predictive value of 97.45% for macrosomia⁽³⁰⁾. There is a strong association between waists to hip ratio and the delivery of a macrosomic newborn independent of BMI. This association suggests that central adiposity may be linked with the mechanism leading to macrosomia in the newborn⁽³¹⁾. Women with a history of one macrosomic infant are at significantly increased risk of another macrosomic infant in a subsequent pregnancy. For women with two or more macrosomic infants, the risk is even greater^(32,33).

Shoulder dystocia occurs in 0.2 to 3 percent of all births and represents an obstetric emergency. It occurs when the

shoulders fail to traverse the pelvis after delivery of the head. The problem lies at the pelvic inlet. In most cases, the posterior shoulder enters the pelvis but the anterior shoulder remains lodged above the symphysis pubis⁽³⁴⁾. Few shoulder dystocia can be anticipated and prevented, as most occur in the absence of risk factors. Brachial plexus injury is one of the most serious fetal complications, and occurs in 2 to 16 percent of shoulder dystocia. Most cases could be resolved, but up to 30 percent result in permanent neurologic impairment⁽³⁵⁾.

Among fetal factors, LGA status is generally considered the most predictive of shoulder dystocia. The incidence of shoulder dystocia increases progressively as birth weight increases over 4000 g⁽³⁶⁾, and morbidity and mortality from shoulder dystocia increase significantly when birth weight is ≥ 4500 g⁽³⁷⁾. Although birth weight is a risk factor for shoulder dystocia, it is not highly useful for predicting its occurrence because:

- The majority of extremely high birth weight infants do not have shoulder dystocia. It was reported in only 15.5 percent of 7859 infants with birth weight ≥ 5000 g delivered vaginally in one series⁽³⁸⁾.

- Approximately 50 percent of shoulder dystocia occur in infants with birth weight <4000 g⁽¹¹⁾.

- It is difficult to predict birth weight prior to delivery. The sensitivity of ultrasonographic examination to detect fetal weight >4500 g ranged from 22 to 69 percent only in one study⁽³⁹⁾. Clinical estimates of birth weight based upon Leopold's maneuvers are also insensitive.

Among maternal risk factors, diabetes in pregnancy is considered the most significant risk factor⁽⁴⁰⁾. The likelihood of shoulder dystocia increases several fold over the non-diabetic population, due, in part, to the higher prevalence of macrosomia in women with diabetes compared with non-diabetic women⁽¹¹⁾. The chest-to-head and shoulder-to-head ratios are increased in DM, thereby increasing the risk of shoulder dystocia independent of fetal weight and at weights <4000 g⁽⁸⁾. Even a single abnormal glucose value in a 75 g two-hour glucose tolerance test is associated with adverse pregnancy outcome, including macrosomia and shoulder dystocia⁽²⁾.

Shoulder dystocia recurs in 1-25 percent of subsequent pregnancies in retrospective studies⁽⁴¹⁾. This may be underestimated since many patients and clinicians choose an abdominal delivery in pregnancies subsequent to an episode of shoulder dystocia. The combination of a previous shoulder dystocia and LGA is particularly worrisome⁽⁴²⁾. Of note, the absence of shoulder dystocia in a previous pregnancy does not preclude its occurrence in a subsequent pregnancy⁽⁴³⁾.

A relationship between shoulder dystocia and abnormal labor progress, including both precipitous and prolonged second stage, has been reported at both high and average birth weights, but data are inconsistent⁽⁴⁴⁾ because of the high frequency of labor abnormalities in the general obstetrical population and the relatively low frequency of shoulder dystocia⁽⁴⁵⁾.

Post-term pregnancy is a risk factor for shoulder dystocia, presumably because of higher birth weights with

advancing gestational age. In a cohort study of term ($n = 379.445$) and post-term ($n = 65.796$) births from Norway, the relative risk of shoulder dystocia in post-term births was increased by 30 percent (RR 1.3, 95% CI 1.2-1.4)⁽⁴⁶⁾.

Male gender is more common in pregnancies complicated by shoulder dystocia than in the overall birth population (55 to 68 percent versus 51 percent)⁽⁴⁷⁾. Several fetal biometric parameters (i.e. difference between the fetal abdominal and biparietal diameters, chest circumference, humerospinous distance, cheek-to-cheek diameter, and shoulder width) have been used to predict shoulder dystocia, primarily in fetuses of diabetic gravidas⁽⁴⁸⁾. The value of this approach has not been tested in large prospective studies. However, most often shoulder dystocia presents without any identifiable prior risk factors and over 90% of the cases of shoulder dystocia occur in babies weighing less than 4500 g⁽⁴⁹⁾. For predicting shoulder dystocia, risk factors have a limited use. Currently, the one most used is estimated fetal weight, but the positive predictive value of macrosomia alone is only 3.3%^(50,51).

LGA infants are more likely to develop respiratory distress than AGA infants⁽⁵²⁾, due to the increased risk of respiratory distress syndrome in infants of diabetic mothers who are more likely to be delivered prematurely. In a report based upon data from the Netherlands Perinatal Registry from 1997 to 2002, the incidence of hypoglycemia was about 19 percent in all LGA infants and 15 percent in LGA infants of nondiabetic mothers⁽⁵³⁾.

It was seen that polycythemia occurs more frequently in LGA infants of both diabetic and nondiabetic mothers compared with AGA infants⁽⁵⁴⁾.

Ultrasound assessment

Fetal macrosomia is a continuing challenge in obstetrics practice. Attempts at the prenatal diagnosis have proven difficult with many series reporting a positive predictive value of only 50%. Sonography is most predictive, albeit not highly accurate, even when performed near term in singleton, cephalic presenting, non-diabetic pregnancies. Performing a single estimation at 29 to 34 weeks of gestation has very poor predictive value for birth weight at term. At this time can significantly underestimate birth weight, probably because of accelerated growth in the later part of the third trimester⁽⁵⁵⁾.

AC is the most common and reliable single parameter used to assess risk of macrosomia⁽⁵⁶⁾. It is measured on a defined plane incorporating the liver since growth abnormalities are often reflected by changes in liver size⁽⁵⁷⁾. The most commonly used thresholds for prediction of macrosomia are ACs of 35 to 38 cm⁽⁵⁸⁾. The sensitivity of the AC measurement depends upon the cut-off chosen, definition of macrosomia, and gestational timing of the examination. The AC measurement is equally accurate whether determined in two dimensions or by an elliptical estimate⁽⁵⁹⁾.

Ultrasound biometry, the only practical method used to detect fetal weight over 4000 g, is characterized by low sensitivity, low positive predictive value, high negative predictive value⁽⁶⁰⁾ and inherent inaccuracies, with large

intra- and inter-observer variability⁽¹¹⁾. Studies at term and intrapartum give a 6-11% mean absolute error when compared with the actual birth weight⁽⁶¹⁾. Since the fetus is an irregular, three-dimensional structure of varying density, the ability of formulas to predict fetal weight has been limited, without good sensitivity and specificity. In addition, sonographic measurement does not permit differentiation between pathologically large and large but healthy infants⁽⁶²⁾.

Most commonly, a combination of biparietal diameter (BPD), head circumference (HC), AC, and femur length (FL) is used. The most popular formulas are Hadlock's⁽⁶³⁾ and Warsof's⁽⁶⁴⁾ with Shepard's modification⁽⁶⁵⁾. Comparisons of these formulas concluded that the formula using BPD, FL and AC (second Hadlock formula) resulted in the best estimate of fetal weight, while the formula using only BPD and AC (Shepard formula) had the least accurate estimate⁽⁶⁶⁾. Formulas for estimating fetal weight perform better for normal sized fetuses than for macrosomic ones^(8,67). The majority of studies conducted to date used a fixed threshold (i.e. estimated fetal weight >4000 g or 4500 g) to compare the accuracy of different models for the detection of macrosomia, a threshold which, as described earlier, does not necessarily represent the optimal threshold for this purpose⁽⁶⁸⁾. O'Reilly-Green and Divon found that the optimal threshold for the detection of macrosomia using the model of Hadlock and contributors was 3711 g rather than 4000 g⁽⁶⁹⁾. As a result, comparison of models using such a fixed threshold may not reflect the true relative accuracy of the different models. A systematic review that compared the accuracy of sonographic (16 different formulas with various combinations of BPD, HC, AC, and FL) and AC in the prediction of macrosomia analyzed 63 studies included 19.117 women⁽⁷⁰⁾.

A rounder fetal head, quantified by a small occipitofrontal diameter (OFD) and normal HC (with a larger BPD/OFD ratio), may contribute to shoulder dystocia by either transiting the pelvis more quickly than a more oval-shaped head, or failing to rotate such that the fetal shoulders incorrectly present at the pelvic inlet⁽⁷¹⁾.

Estimating fetal weight by ultrasonographic measurement prior to induction of labor could potentially be even more problematic owing to the low position of the head and an increased risk of abdominal circumference distortion or posterior position of the femur at this late gestation^(72,73). Similarly, including maternal weight in weight-estimation formulas also improves the accuracy, to a mean absolute percentage error of 3.69 percent with 97.1 percent of fetuses within 10 percent of actual birth weight^(74,75). However, predictions of macrosomia by these techniques are limited by the substantial false-positive and false-negative rates inherent in these tests⁽⁷⁶⁾.

The majority of sonographic formulas do not take body composition into account. Because body composition can vary greatly, even in the fetus, significant variation in birth weight can occur among fetuses with similar biometric parameters. Body fat accounts for 14 percent of the birth weight in neonates, but 46 percent of birth weight variance⁽⁷⁷⁾. Ultrasound has been used to assess subcutaneous

fat at the mid humerus⁽⁷⁸⁾, shoulder⁽⁷⁹⁾, abdominal wall⁽⁸⁰⁾, thigh⁽⁸¹⁾, and peribucal area⁽⁸²⁾ to provide better evaluation of normal and disturbed growth⁽⁷⁷⁾. Combinations of soft tissue measurements or other parameters (i.e. umbilical cord cross section or amniotic fluid volume) with estimation of fetal weight (EFW) may be more useful for predicting macrosomia than any method alone^(82,83).

The sonographic measurements described above estimate weight using two-dimensional principles on a three-dimensional subject. Improvements in imaging technologies have helped alleviate this problem, leading to better weight estimation. Volumetric measurement by two-dimensional ultrasound can be calculated using the formula: $EFW = (0.23718 \times AC^2 \times FL) + (0.03312 \times HC^3)$. When compared to the traditional calculation of EFW using Shepard or Hadlock formulas, this method had fewer systematic and absolute errors (mean percent error was 6.2%)⁽⁸⁴⁾.

Three-dimensional ultrasound has heightened interest in using volumetric estimates to predict fetal macrosomia. Validation studies for EFW showed similarities between three-dimensional and two-dimensional measures in systemic error measurements of fetal thigh, AC and estimated weight precision⁽⁸⁵⁾. Most predictions were within 10 percent of true birth weight. Subsequent studies incorporated measurement of single parameters, such as the fetal upper arm⁽⁸⁶⁾ and thigh⁽⁸⁷⁾, which also correlated well to birth weight. Better qualitative analysis of fetal soft tissue may be possible with three-dimensional ultrasound, allowing for improved estimation of actual birth weight⁽⁸⁸⁾. The best ability to predict macrosomia comes from combining three-dimensional volumetric measurements (i.e. volume of upper arms, thigh and abdomen) with two-dimensional measurements (formula = $-1478.557 + 7.242 \times \text{thigh vol} + 13.309 \times \text{upper arm vol} + 852.998 \times \log_{10} \text{AC vol} + 0.526 \times \text{BPD3}$)⁽⁸⁹⁾. With combined measurements, the mean absolute percentage of error was 6.5 percent versus 10 to 15 percent with two-dimensional alone.

Magnetic resonance imaging (MRI) should be, in theory, a superior technique for evaluation of macrosomia because it evaluates fat better than ultrasound⁽⁹⁰⁾. Some results have been encouraging. In one study, the median difference between MRI-derived EFW and actual birth weight was 3 percent, as opposed to 6.5 percent for ultrasound-derived EFW⁽⁹¹⁾. In addition, a small, but well designed, study demonstrated a significant correlation between MRI prediction of fetal shoulder measurements of fetuses with suspected macrosomia and the actual shoulder width⁽⁹²⁾.

Sonographic EFW has been combined with results of the glucose challenge test to better predict macrosomia. When sonographic EFW was >4000 g, the presence of a glucose challenge test (GCT) ≥ 120 mg/dL had a positive predictive value of 71 percent for macrosomia compared to 60 percent with GCT ≤ 120 mg/dL⁽⁹³⁾. The mean absolute percent error is greater in infants weighing above 4500 g (12.6 versus 8.4 percent if below 4500 g), regardless of diabetic status⁽⁹⁴⁾.

A study comparing three EFW formulas using multiple parameters versus prediction of birth weight by AC alone concluded that measurement of AC was quicker and similarly accurate. All formulas were associated with an error of ± 20 to 25 percent⁽⁹⁵⁾. Another study reported that AC >70 percentile is predictive of poor glycemic control and increased risk of macrosomia⁽⁹⁶⁾. Based on these findings, the American Diabetes Association recommended the use of AC $>75^{\text{th}}$ percentile as a measure of glycemic control and risk for macrosomia in diabetic gravidas⁽⁹⁷⁾.

Some investigators have combined ultrasonography with pregnancy-specific data (i.e. parity, ethnicity, BMI, maternal height, weight and weight gain) to create nomograms for detecting fetal macrosomia, but these methods have not performed well consistently⁽⁹⁸⁻¹⁰⁰⁾. Mazouni and contributors⁽⁹⁹⁾ published a nomogram for individual prediction of macrosomia (birth weight >4000 g) based on maternal characteristics and the presence or absence of an EFW ≥ 4000 g at ultrasound examination performed within 1 week of delivery. Their formula was found to be superior to the four Hadlock formulae for EFW. In contrast to the results of Nahum and Stanislaw, Ben-Haroush and contributors⁽¹⁰¹⁾ did not find any evidence that the prediction of LGA at birth could be improved by adding clinical information to the ultrasonically EFW. The longer the period between ultrasound examination and delivery, the more time there is for maternal factors to influence fetal growth⁽¹⁰²⁾.

The 39-week scan being performed on a high risk population with a higher prevalence of large fetuses would therefore be more likely to achieve clinically useful, especially if a targeted formula for macrosomia and the latest ultrasound three-dimensional volumetric studies or even MRI were utilized^(85,102).

Clinical assessment

Fetal weight can be estimated clinically by palpation of the fetus through the maternal abdomen (i.e. Leopold maneuvers) and/or by measurement of fundal height. The capacity for antepartum diagnosis of fetal macrosomia in the general obstetrical population by clinical means is limited, but is somehow better in patients at higher risk. Symphyseal-fundal height varies with gestational age and maternal characteristics and the combination of these two parameters gives improved EFW than when symphyseal-fundal height alone is considered⁽⁹⁹⁾. Although, in general, clinical estimates of birth weight perform favorably, ultrasound immediately prior to labor is more accurate at predicting the low- or high-birth weight fetus⁽⁷²⁾. All women thought to be at risk should be delivered in a fully-equipped maternity unit⁽¹⁰³⁾.

Planning delivery in pregnancies at risk

Patient safety is about minimizing error and preventing harm. Reasons for errors include human fallibility, medical complexity, system deficiencies, and defensive barriers. Medical errors do not spare obstetric population and it is likely that strategies to reduce these errors would benefit pregnant women and their children⁽¹⁰⁴⁾.

If there is delay in the late active phase of labour (7-10 cm) or failure of descent in the second stage, careful evaluation is advised before vaginal delivery is allowed. If there is evidence of fetal hypoxia or the possibility of mid-pelvic extraction, cesarean section may be indicated. Clinical judgment and appropriate caution should replace any hard-and-fast rules requiring caesarean delivery⁽¹⁰⁵⁾. The clinical approach that has evolved is to attempt identification of those pregnancies most likely to result in shoulder dystocia with long-term complications and then avoid vaginal delivery of them. The American College of Obstetricians and Gynecologists Task Force on Neonatal Brachial Plexus Palsy, identified the following clinical situations as high risk for shoulder dystocia and brachial plexus injury⁽¹⁰⁶⁾:

- Estimated fetal weight >5000 g in women without diabetes or >4500 g in women with diabetes

- Prior shoulder dystocia, especially with a severe neonatal injury

- Mid pelvic operative vaginal delivery of a fetus with estimated weight >4000 g

Cesarean delivery in these scenarios is a reasonable option as it should reduce the occurrence of shoulder dystocia and associated morbidity. In fact, brachial plexus injury has been reported even after caesarean delivery. Thus, cesarean delivery reduces but does not eliminate the risk of birth trauma associated with macrosomia⁽¹⁰⁷⁾. A policy of routine prophylactic cesarean delivery for all cases of suspected high birth weight would likely result in many unnecessary cesarean births of both normal weight and high birth weight neonates⁽¹⁰⁸⁾. Even if newborns weighing over 4000 g could have been accurately predicted, routine cesarean

section would have prevented just 57% of the shoulder dystocia cases but not one permanent injury⁽¹⁰⁹⁾.

The medical literature does not support elective cesarean section for suspected fetal macrosomia in non-diabetic women⁽¹¹⁰⁾. A woman with a height >175 cm has a significantly lower chance of shoulder dystocia and trial of labor might be chosen. No pressure should be placed on the couple and, once they have decided, there is no need to revisit the issue unless the couple requests it. The couple should be supported in the decision they make. This is a situation in which maternal autonomy is paramount. For babies weighing 4.5 kg or more, the emergency cesarean section rate is 45%⁽¹¹¹⁾ and the instrumental delivery rate 19%⁽¹¹²⁾.

Induction of labour does not improve outcomes in the setting of suspected fetal macrosomia and may increase cesarean deliveries. Induction of labour in women with diabetes in pregnancy have been shown to reduce fetal macrosomia⁽¹¹³⁾.

Conclusions

In the light of the worldwide obesity epidemic, perinatal complications caused by fetal macrosomia will be an increasing phenomenon in the near future. Early identification of fetuses at risk for macrosomia will therefore be an issue of increasing importance in obstetrics. These women could then be offered extra ultrasound examinations enabling fetal growth follow-up, possibly employing more sophisticated techniques such as three dimensional ultrasound, and individual planning for time and mode of delivery. Such a clinical protocol might prevent perinatal complications due to fetal macrosomia, and thus benefit both the mother and the neonate. ■

References

1. ACOG Practice Bulletin No.22: Fetal Macrosomia. American College of Obstetricians and Gynecologists, Washington DC 2000.
2. Modanlou HD, Dorchester WL, Thorosian A, Freeman RK. Macrosomia-maternal, fetal, and neonatal implications. *Obstet Gynecol* 1980, 55(4), 420-4.
3. Boyd ME, Usher RH, McLean FH. Fetal macrosomia: prediction, risks, proposed management. *Obstet Gynecol* 1983, 61(6), 715-22.
4. Boulet SL, Alexander GR, Salihu HM, Pass M. Macrosomic births in the united states: determinants, outcomes, and proposed grades of risk. *Am J Obstet Gynecol* 2003, 188(5), 1372-8.
5. Langer O, Berkus MD, Huff RW, Samueloff A. Shoulder dystocia: should the fetus weighing greater than or equal to 4000 grams be delivered by cesarean section? *Am J Obstet Gynecol* 1991, 165(4 Pt.1), 831-7.
6. Siggekkow W, Boehm D, Skala C, Grosslercher M, Schmidt M, Koelbl H. The influence of macrosomia on the duration of labor, the mode of delivery and intrapartum complications. *Arch Gynecol Obstet* 2008, 278, 547-53.
7. Stotland NE, Caughey AB, Breed EM, Escobar GJ. Risk factors and obstetric complications associated with macrosomia. *Int J Gynaecol Obstet* 2004, 87, 220-6.
8. Chauhan SP, Grobman WA, Gherman RA, Chauhan VB, Chang G, Magann EF, Hendrix NW. Suspicion and treatment of the macrosomic fetus: a review. *Am J Obstet Gynecol* 2005, 193(2), 332-46.
9. Koyanagi A, Zhang J, Dagvadorj A, Hirayama F, Shibuya K, Souza JP, Gulmezoglu AM. Macrosomia in 23 developing countries: an analysis of a multicountry, facility-based, cross-sectional survey. *Lancet* 2013, 381, 476-83.
10. Kennedy MC, Dunne F. Macrosomia: defining the problem worldwide. *Lancet* 2013, 381(9865), 435.
11. Zhang X, Decker A, Platt RW, Kramer MS. How big is too big? The perinatal consequences of fetal macrosomia. *Am J Obstet Gynecol* 2008, 198, 517e1.
12. Surkan PJ, Hsieh C-C, Johansson ALV, Dickman PW, Cnattingius S. Reasons for increasing trends in large for gestational age births. *Obstet Gynecol* 2004, 104, 720-6.
13. Grassi AE, Giuliano MA. The neonate with macrosomia. *Clin Obstet Gynecol* 2000, 43, 340-8.
14. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. *Lancet* 1992, 339, 283-7.
15. Lindell G, Marsal K, Kallen K. Impact of maternal characteristics on fetal growth in the third trimester: a population-based study. *Ultrasound Obstet Gynecol* 2012, 40, 680-7.
16. Henriksen T. The macrosomic fetus: a challenge in current obstetrics. *Acta Obstet Gynecol Scand* 2008, 87, 134-45.
17. Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. *BMJ* 2004, 328(7445), 915.
18. Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M, Beck Nielsen H. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. *Diabetes Care* 2004, 27, 2819-23.
19. Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. *Diabetes Care* 2006, 29, 1744-9.
20. Clausen TD, Mathiesen E, Ekbohm P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. *Diabetes Care* 2005, 28, 323-8.
21. Lapolla A, Dalfr' a MG, Bonomo M, Parretti E, Mannino D, Mello G, Di Cianni G. Scientific Committee of GISOGD Group. Gestational diabetes mellitus in Italy: a multicenter study. *Eur J Obstet Gynecol Reprod Biol* 2009, 145, 149-53.
22. Kuc S, Wortelboer EJ, Koster MP, de Valk HW, Schielen PC, Visser GHA. Prediction of macrosomia at birth in type-1 and diabetic pregnancies with biomarkers of early placentation. *BJOG* 2011, 118, 748-54.
23. Bracero LA, Baxi LV, Rey HR, Yeh MN. Use of ultrasound in antenatal diagnosis of large-for-gestational age infants in diabetic gravid patients. *Am J Obstet Gynecol* 1985, 152(1), 43-7.
24. Lepercq J, Taupin P, Dubois-Laforgue D, Duranteau L, Lahlou N, Boitard C, Landais P, Hauguel-De Mouzon S, Timsit J. Heterogeneity of fetal growth in type 1 diabetic pregnancy. *Diabetes Metab* 2001, 27, 339-44.
25. Durnwald C, Huston-Presley L, Armini S, Catalano P. Evaluation of body composition of large-for-gestational-age infants of women with gestational diabetes mellitus compared with women with normal glucose tolerance levels. *Am J Obstet Gynecol* 2004, 191(3), 804-8.
26. Wong SF, Chan FY, Cincotta RB, Oats J, McIntyre HD. Fetal growth spurt and pre-gestational diabetic pregnancy. *Diabetes Care* 2002, 25, 1681-4.
27. Bethune M, Bell R. Evaluation of the measurement of the fetal fat layer, intraventricular septum and abdominal circumference percentile in the prediction of macrosomia in pregnancies affected by gestational diabetes. *Ultrasound Obstet Gynecol* 2003, 22(6), 586-90.
28. Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia in the average-weight infant. *Obstet Gynecol* 1986, 67, 614-8.
29. Ehremberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. *Am J Obstet Gynecol* 2004, 191, 964-8.
30. Asplund CA, Seehusen DA, Callahan TL, Olsen C. Percentage change in antenatal body mass index as a predictor of neonatal macrosomia. *Ann Fam Med* 2008, 6, 550-4.
31. Salem W, Adler A, Lee C, Smith G. Maternal waist to hip ratio is a risk factor for macrosomia. *BJOG* 2012, 119, 291-7.
32. Walsh CA, Mahony RT, Foley ME, Daly L, O'Herlihy C. Recurrence of fetal macrosomia in non-diabetic pregnancies. *J Obstet Gynaecol* 2007, 27, 374-8.
33. Vora N, Bianchi DW. Genetic considerations in the prenatal diagnosis of overgrowth syndromes. *Prenat Diagn* 2009, 29(10), 923-9.

References

34. Smeltzer J. Prevention and management of shoulder dystocia. *Clin Obstet Gynecol* 1986, 29, 299-308.
35. Foad SL, Mehman CT, Foad MB, Lippert WC. Prognosis following neonatal brachial plexus palsy: an evidence-based review. *J Child Orthop* 2009, 3(6), 459-63.
36. Vidarsdottir H, Geirsson RT, Hardardottir H, Valdimarsdottir U, Dagbjartsson A. Obstetric and neonatal risks among extremely macrosomic babies and their mothers. *Am J Obstet Gynecol* 2011, 204, 423.e1-6.
37. Sandmire HF, O'Hallion TJ. Shoulder dystocia: its incidence and associated risk factors. *Int J Gynaecol Obstet* 1988, 26, 65-73.
38. Boulet SL, Alexander GR, Salihu HM, Pass M. Macrosomic births in the United States: determinants, outcomes, and proposed grades of risk. *Am J Obstet Gynecol* 2003, 188, 1372-8.
39. Øverland EA, Vatten LJ, Eskild A. Pregnancy week at delivery and the risk of shoulder dystocia: a population study of 2,014,956 deliveries. *BJOG* 2014, 12, 34-41.
40. Gottlieb A, Galan H. Shoulder dystocia: an update. *Obstet Gynecol Clin N Am* 2007, 34, 501-31.
41. Overland EA, Spydslaag A, Nielsen CS, Eskild A. Risk of shoulder dystocia in second delivery: does a history of shoulder dystocia matter? *Am J Obstet Gynecol* 2009, 200, 506.e1-6.
42. Usta IM, Hayek S, Yahya F, Abu-Musa A, Nassar AH. Shoulder dystocia: what is the risk of recurrence? *Acta Obstet Gynecol Scand* 2008, 87, 992-7.
43. Belfort MA, Dildy GA, Saade GR, Suarez V, Clark SL. Prediction of shoulder dystocia using multivariate analysis. *Am J Perinatol* 2007, 24(1), 5-10.
44. Mahony R, Walsh C, Foley ME, Daly L, O'Herlihy C. Outcome of second delivery after prior macrosomic infant in women with normal glucose tolerance. *Obstet Gynecol* 2006, 107(4), 857-62.
45. ACOG Committee on Practice Bulletins-Gynecology, The American College of Obstetrician and Gynecologists. ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002. *Obstet Gynecol* 2002, 100(5 Pt 1), 1045-50.
46. McFarland M, Hod M, Piper JM, et al. Are labor abnormalities more common in shoulder dystocia? *Am J Obstet Gynecol* 1995, 173(4), 1211-4.
47. MacKenzie IZ, Shah M, Lean K, Dutton S, Newdick H, Tucker DE. Management of shoulder dystocia: trends in incidence and maternal and neonatal morbidity. *Obstet Gynecol* 2007, 110(5), 1059-68.
48. Cheng YW, Norwitz ER, Caughey AB. The relationship of fetal position and ethnicity with shoulder dystocia and birth injury. *Am J Obstet Gynecol* 2006, 195(3), 856-62.
49. Gonen R, Spiegel D, Abend M. Is macrosomia predictable, and are shoulder dystocia and birth trauma preventable? *Obstet Gynecol* 1996, 88, 526-8.
50. Geary M, McParland P, Johnson H, Stronge J. Shoulder dystocia - is it predictable? *Eur J Obstet Gynecol Reprod Biol* 1995, 62, 15-8.
51. Campbell S. Fetal macrosomia: a problem in need of a policy. *Ultrasound Obstet Gynecol* 2014, 43, 3-10.
52. Gillean JR, Coonrod DV, Russ R, Bay RC. Big infants in the neonatal intensive care unit. *Am J Obstet Gynecol* 2005, 192(6), 1948-53.
53. Groenendaal F, Elferink-Stinkens PM. Hypoglycaemia and seizures in large-for-gestational-age (LGA) full-term neonates. *Acta Paediatr* 2006, 95(7), 874-6.
54. Dollberg S, Marom R, Mimouni FB, Yeruchimovich M. Normoblasts in large for gestational age infants. *Arch Dis Child Fetal Neonatal Ed* 2000, 83(2), F148-F9.
55. Ben-Haroush A, Chen R, Hadar E, Hod M, Yogev Y. Accuracy of a single fetal weight estimation at 29-34 weeks in diabetic pregnancies: can it predict large-for-gestational-age infants at term? *Am J Obstet Gynecol* 2007, 197(5), 497.e1-6.
56. Rosati P, Arduini M, Giri C, Guariglia L. Ultrasonographic weight estimation in large for gestational age fetuses: a comparison of 17 sonographic formulas and four models algorithms. *J Matern Fetal Neonatal Med* 2010, 23(7), 675-80.
57. Deter RL, Harrist RB. Assessment of Normal Fetal Growth. In: *Ultrasound in Obstetrics and Gynecology*, 1st ed, Chervenak FA, Isaacson GC, Campbell S (Eds), Little, Brown and Company, Boston 1993, 361.
58. Gilby JR, Williams MC, Spellacy WN. Fetal abdominal circumference measurements of 35 and 38 cm as predictors of macrosomia. A risk factor for shoulder dystocia. *J Reprod Med* 2000, 45(11), 936-8.
59. Smulian JC, Ranzini AC, Ananth CV, Rosenberg JC, Vintzileos AM. Comparison of three sonographic circumference measurement techniques to predict birth weight. *Obstet Gynecol* 1999, 93(5 Pt 1), 692-6.
60. Ben-Haroush A, Yogev Y, Hod M. Fetal weight estimation in diabetic pregnancies and suspected fetal macrosomia. *J Perinat Med* 2004, 32, 113-21.
61. Fuglsang J, Lauszus FF, Fisker S, Flyvbjerg A, Ovesen P. Growth hormone binding protein and maternal body mass index in relation to placental growth hormone and insulin requirements during pregnancy in type 1 diabetic women. *Growth Horm IGF Res* 2005, 15, 223-30.
62. Keller JD, Metzger BE, Dooley SL, Tamura RK, Sabbagha RE, Freinkel N. Infants of diabetic mothers with accelerated fetal growth by ultrasonography: are they all alike? *Am J Obstet Gynecol* 1990, 163(3), 893-7.
63. Hadlock FP, Harrist RB, Sharnam RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. *Am J Obstet Gynecol* 1985, 151(3), 333-7.
64. Warsof SL, Gohari P, Berkowitz RL, Hobbins JC. The estimation of fetal weight by computer-assisted analysis. *Am J Obstet Gynecol* 1977, 128(8), 881-92.
65. Shepard MJ, Richards VA, Berkowitz RL, Warsof SL, Hobbins JC. An evaluation of two equations for predicting fetal weight by ultrasound. *Am J Obstet Gynecol* 1982, 142(1), 47-54.
66. Faschingbauer F, Voigt F, Goecke TW, Siemer J, Beckmann MW, Yazdi B, Schild RL. Fetal weight estimation in extreme macrosomia ($\geq 4,500$ g): comparison of 10 formulas. *Ultraschall Med* 2012, 33(7), E62-7.
67. Weiner Z, Ben-Shlomo I, Beck-Fruchter R, Goldberg Y, Shalev E. Clinical and ultrasonographic weight estimation in large for gestational age fetus. *Eur J Obstet Gynecol Reprod Biol* 2002, 105(1), 20-4.
68. Melamed N, Yogev Y, Meizner I, Mashiah R, Pardo J, Ben-Haroush A. Prediction of fetal macrosomia: effect of sonographic fetal weight-estimation model and threshold used. *Ultrasound Obstet Gynecol* 2011, 38, 74-81.
69. O'Reilly-Green CP, Divon MY. Receiver operating characteristic curves of sonographic estimated fetal weight for prediction of macrosomia in prolonged pregnancies. *Ultrasound Obstet Gynecol* 1997, 9, 403-8.
70. Coomarasamy A, Connock M, Thornton J, Khan KS. Accuracy of ultrasound biometry in the prediction of macrosomia: a systematic quantitative review. *BJOG* 2005, 112(11), 1461-6.
71. Belfort MA, White G L, Vermeulen FM. Association of fetal cranial shape with shoulder dystocia. *Ultrasound Obstet Gynecol* 2012, 39, 304-9.
72. Peregrine E, O'Brien P, Jauniaux E. Clinical and ultrasound estimation of birth weight prior to induction of labor at term. *Ultrasound Obstet Gynecol* 2007, 29, 304-9.
73. Sokol RJ, Chik L, Dombrowski MP, Zador IE. Correctly identifying the macrosomic fetus: improving ultrasonography-based prediction. *Am J Obstet Gynecol* 2000, 182(6), 1489-95.
74. Hart NC, Hilbert A, Meurer B, Schrauder M, Siemer J, Voigt M, Schild RL. Macrosomia: a new formula for optimized fetal weight estimation. *Ultrasound Obstet Gynecol* 2010, 35, 42-7.
75. Hackmon R, Bornstein E, Ferber A, Horani J, O'Reilly Green CP, Divon MY. Combined analysis with amniotic fluid index and estimated fetal weight for prediction of severe macrosomia at birth. *Am J Obstet Gynecol* 2007, 196, 333, e1-4.
76. O'Reilly-Green C, Divon M. Sonographic and clinical methods in the diagnosis of macrosomia. *Clin Obstet Gynecol* 2000, 43, 309-20.
77. Bernstein IM, Catalano PM. Influence of fetal fat on the ultrasound estimation of fetal weight in diabetic mothers. *Obstet Gynecol* 1992, 79(4), 561-3.
78. Sood AK, Yancey M, Richards D. Prediction of fetal macrosomia using humeral soft tissue thickness. *Obstet Gynecol* 1995, 85(6), 937-40.
79. Mintz MC, Landon MB, Gabbe SG, Marinella DL, Ludmir J, Grumbach K, Arger PH, Coleman BG. Shoulder soft tissue width as a predictor of macrosomia in diabetic pregnancies. *Am J Perinatol* 1989, 6(2), 240-3.
80. Petrikovsky BM, Oleschuk C, Lesser M, Gelertner N, Gross B. Prediction of fetal macrosomia using sonographically measured abdominal subcutaneous tissue thickness. *J Clin Ultrasound* 1997, 25(7), 378-82.
81. Rigano S, Ferrazzi E, Radaelli T, Cetin ET, Pardi G. Sonographic measurements of subcutaneous fetal fat in pregnancies complicated by gestational diabetes and in normal pregnancies. *Croat Med J* 2000, 41(3), 240-4.
82. Chauhan SP, West DJ, Scardo JA, Boyd JM, Joiner J, Hendrix NW. Antepartum detection of macrosomic fetus: clinical versus sonographic, including soft-tissue measurements. *Obstet Gynecol* 2000, 95(5), 639-42.
83. Cromi A, Ghezzi F, Di Naro E, Siesto G, Raio L. Large cross-sectional area of the umbilical cord as a predictor of fetal macrosomia. *Ultrasound Obstet Gynecol* 2007, 30, 861-6.
84. Combs CA, Rosenn B, Miodovnik M, Siddiqi TA. Sonographic EFW and macrosomia: is there an optimum formula to predict diabetic fetal macrosomia? *J Matern Fetal Med* 2000, 9(1), 55-61.
85. Lee W, Comstock CH, Kirk JS, Smith RS, Monck JW, Deenadayalu R, Bendick PJ. Birthweight prediction by three-dimensional ultrasonographic volumes of the fetal thigh and abdomen. *J Ultrasound Med* 1997, 16(12), 799-805.
86. Liang RI, Chang FM, Yao BL, Chang CH, Yu CH, Ko HC. Predicting birth weight by fetal upper-arm volume with use of three-dimensional ultrasonography. *Am J Obstet Gynecol* 1997, 177(3), 632-8.
87. Song TB, Moore TR, Lee JI, Kim YH, Kim EK. Fetal weight prediction by thigh volume measurement with three-dimensional ultrasonography. *Obstet Gynecol* 2000, 96(2), 157-61.
88. Matsumoto M, Yanagihara T, Hata T. Three-dimensional qualitative sonographic evaluation of fetal soft tissue. *Hum Reprod* 2000, 15(11), 2438-42.
89. Schild RL, Fimmers R, Hansmann M. Fetal weight estimation by three-dimensional ultrasound. *Ultrasound Obstet Gynecol* 2000, 16(5), 445-52.
90. Duncan KR. Fetal and placental volumetric and functional analysis using echoplanar imaging. *Top Magn Reson Imaging* 2001, 12(1), 52-66.
91. Baker PN, Johnson IR, Gowland PA, Hykin J, Harvey PR, Freeman A, Adams V, Worthington BS, Mansfield P. Fetal weight estimation by echo-planar magnetic resonance imaging. *Lancet* 1994, 343(8898), 644-5.
92. Tuveva TA, Salmi H, Poutanen VP, Karjalainen PT, Hytintanti T, Paavonen J, Teramo KA, Aronen HJ. Fetal shoulder measurements by fast and ultrafast MRI techniques. *J Magn Reson Imaging* 2001, 13(6), 938-42.
93. Sylvestre G, Divon MY, Onyeije C, Fisher M. Diagnosis of macrosomia in the postdates population: combining sonographic estimates of fetal weight with glucose challenge testing. *J Matern Fetal Med* 2000, 9(5), 287-90.
94. Alsulyman OM, Ouzounian JG, Kjos SL. The accuracy of intrapartum ultrasonographic fetal weight estimation in diabetic pregnancies. *Am J Obstet Gynecol* 1997, 177(3), 503-6.
95. Farrell T, Fraser R, Chan K. Ultrasonic fetal weight estimation in women with pregnancy complicated by diabetes. *Acta Obstet Gynecol Scand* 2004, 83(11), 1065-6.
96. Kjos SL, Schaefer-Graf U, Sardesi S, Peters RK, Buley A, Xiang AH, Bryne JD, Sutherland C, Montoro MN, Buchnan TA. A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. *Diabetes Care* 2001, 24(11), 1904-10.
97. Fifth International Workshop-Conference on Gestational Diabetes. November, 2005. Chicago, IL.
98. Balseyte D, Schäffer L, Burkhardt T, Wisser J, Kurmanavicius J. Sonographic prediction of macrosomia cannot be improved by combination with pregnancy-specific characteristics. *Ultrasound Obstet Gynecol* 2009, 33(4), 453-8.
99. Mazouni C, Rouzier R, Leduc R, Heckenroth H, Guidicelli B, Gamerre M. Development and internal validation of a nomogram to predict macrosomia. *Ultrasound Obstet Gynecol* 2007, 29(5), 544-9.
100. Nahum GG, Stanislav H. A computerized method for accurately predicting fetal macrosomia up to 11 weeks before delivery. *Eur J Obstet Gynecol Reprod Biol* 2007, 133, 148-56.
101. Ben-Haroush A, Yogev Y, Hod M, Bar J. Predictive value of a single early weight estimate in normal pregnancies. *Eur J Obstet Gynecol Reprod Biol* 2007, 130, 187-92.
102. Lindell G, Marsal K, Kallen K. Predicting risk for large-for-gestational age neonates at term: a population-based Bayesian theorem study. *Ultrasound Obstet Gynecol* 2013, 41, 398-405.
103. Mayer C, Joseph KS. Fetal growth: a review of terms, concepts and issues relevant to obstetrics. *Ultrasound Obstet Gynecol* 2013, 41, 136-45.
104. Kohn, LT, Corrigan, JM, Donaldson, MS, Eds; Committee of Quality of Health Care in America, Institute of Medicine. *To Err Is Human: Building a Safer Health System*. Washington, DC: National Academy Press, 1999.
105. Johnstone FD, Myerscough PR. Shoulder dystocia. *British Journal of Obstetrics and Gynaecology* 1998, 105, 811-5.
106. Klajaj FAV, Geirsson RT, Nielsen H, Hreinsdottir M, Haraldsdottir KR. Humerospinous distance measurements: accuracy and usefulness for predicting shoulder dystocia in delivery at term. *Ultrasound Obstet Gynecol* 1998, 12, 115-9.
107. Gherman RB, Ouzounian JG, Goodwin TM, Miller DA, Paul RH. Brachial plexus palsy associated with caesarean section: an in utero injury? *Am J Obstet Gynecol* 1997, 177, 1162-4.
108. American College of Obstetricians and Gynecologists. Executive summary: neonatal brachial plexus palsy. *Obstet Gynecol* 2014, 123(4), 902-4.
109. Nocon JJ, McKenzie DK, Thomas LJ, Hansell RS. Shoulder dystocia: an analysis of risks and obstetric maneuvers. *Am J Obstet Gynecol* 1993, 168, 1732-9.
110. Flamm BL, Goings JR. Vaginal birth after caesarean section: is suspected fetal macrosomia a contraindication? *Obstet Gynecol* 1989, 74, 694-7.
111. Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective caesarean delivery for fetal macrosomia diagnosed by ultrasound. *JAMA* 1996, 276, 1480-6.
112. Kolderup LB, Laros RK Jr, Musci TJ. Incidence of persistent birth injury in macrosomic infants: association with mode of delivery. *Am J Obstet Gynecol* 1997, 177, 37-41.
113. Mozurkewich E, Chilimigras J, Koepke E, Keeton K, King V. Indications for induction of labour: a best-evidence review. *BJOG* 2009, 116, 626-36.